Episode 194 - August 28, 2026

What It Covers

Biotech Hangout Episode 194 covers the XBI's 80% twelve-month rally, Moderna's mRNA cancer vaccine phase three success in melanoma, Revolution Medicines' FDA approval for pancreatic cancer at $478,000 annually, the Heidi Overton FDA commissioner nomination, ATTR cardiomyopathy gene silencer data failure, and escalating drug pricing concerns across newly approved therapies.

Key Questions Answered

• •Biotech M&A vs. Equity Shift: M&A activity in small-to-mid cap biotech has reached $143 billion year-to-date, more than double the $66 billion seen at the 2020–2021 peak, while equity issuance sits at only $59 billion. Investors should note that this M&A-heavy structure, combined with zero preclinical IPOs this cycle versus 19 before the last peak, signals a far more selective and fundamentals-driven capital market environment.
• •Moderna mRNA Cancer Vaccine Franchise Durability: Moderna's INTERPATH-001 phase three trial demonstrated recurrence-free survival and distant metastasis-free survival benefits in resected melanoma patients using a personalized neoantigen mRNA vaccine plus Keytruda. The proprietary algorithm selecting neoantigens is expected to remain a trade secret, meaning no generic version is possible, creating a potentially perpetual franchise with analysts estimating up to $12 billion in non-risk-adjusted peak value.
• •Revolution Medicines RAS(ON)Q Pricing and Label Nuance: Rasaguilib received FDA approval for pancreatic cancer priced at $478,000 annually, exceeding analyst estimates of $275,000 and surpassing most oncology small molecules except Vitrakvy at $518,000. Critically, the label permits use in patients ineligible for chemotherapy as a frontline agent, which could shift prescribing patterns and complicate clinical trial design for next-generation PDAC therapies including PRMT5 inhibitors.
• •ATTR Gene Silencer Class Reassessment: AstraZeneca and Ionis's CardioTRANSFORM phase three study showed eplontersen added no cardiovascular benefit over tafamidis stabilizer alone, with combination patients performing marginally worse. Physicians currently combining Alnylam's vutisiran with stabilizers now lack clinical evidence supporting that practice. Investors should distinguish between antisense and RNAi mechanisms before extrapolating this result to vutisiran's HARMONY-3 readout expected in approximately nine months.
• •FDA Commissioner Nomination Risk Map: Trump nominee Heidi Overton, a physician with a Johns Hopkins PhD and roughly three to four years of government experience, faces Senate confirmation scrutiny over limited management experience and association with vaccine-skeptic health policy. If confirmed, rare diseases, gene therapy, neurology, cell therapy, and precision oncology stand to benefit from clinical trial modernization, while vaccine developers and reproductive health companies face elevated regulatory uncertainty.
• •Drug Pricing Trajectory Benchmark: Newly approved rare disease drugs are pricing at levels that consistently exceed analyst models, with recent rare endocrine approvals averaging $280,000–$285,000 annually and outliers like Brepo exceeding $400,000. Analysts building revenue models should recalibrate pricing assumptions upward toward recent class averages rather than historical midpoints, while monitoring gross-to-net discount structures that can materially reduce net revenue relative to list price.